Showing results (51-60 of 108) with videos related to
Sort By:
Pageof 11
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 11, 2024
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapyRobbin Itzler, Tyler W Buckner, Frank W G Leebeek, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|July 23, 2019
Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitorsDenise E Sabatino, Steven W Pipe, Diane J Nugent, et al.Blood|May 23, 2014
A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in miceAndrew Yee, Robert D Gildersleeve, Shufang Gu, et al.Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Application of a hemophilia mortality framework to the Emicizumab Global Safety DatabaseFlora Peyvandi, Johnny N Mahlangu, Steven W Pipe, et al.Current Medical Research and Opinion|September 28, 2022
Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FPJohannes Oldenburg, Steven W Pipe, Maria Elisa Mancuso, et al.Research and Practice in Thrombosis and Haemostasis|February 24, 2025
Recombinant factor VIIa: new insights into the mechanism of action through product innovationMiguel A Escobar, Maureane Hoffman, Giancarlo Castaman, et al.Research and Practice in Thrombosis and Haemostasis|March 13, 2023
Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxisSteven W Pipe, Ben Trzaskoma, Miranda Minhas, et al.Research and Practice in Thrombosis and Haemostasis|August 14, 2025
Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practiceRobert F Sidonio, Guy Young, Carmen Escuriola Ettingshausen, et al.Research and Practice in Thrombosis and Haemostasis|August 4, 2023
Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]Steven W Pipe, Ben Trzaskoma, Miranda Minhas, et al.Thrombosis and Haemostasis|May 6, 2020
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary ProphylaxisPratima Chowdary, Kathelijn Fischer, Peter W Collins, et al.Pageof 11